Frankfurt - Delayed Quote EUR

Vertex Pharmaceuticals Incorporated (VX1.F)

Compare
440.55 -1.95 (-0.44%)
As of 8:02 AM GMT+2. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Dr. Jeffrey Marc Leiden M.D., Ph.D. Executive Chairman 85.02k -- 1956
Dr. Reshma Kewalramani FASN, M.D. CEO, President & Director 5M 3.45M 1973
Mr. Charles F. Wagner Jr. Executive VP & CFO 1.9M -- 1968
Mr. Stuart A. Arbuckle B.Sc. Executive VP & COO 2.47M 2.87M 1966
Dr. David M. Altshuler M.D., Ph.D. Executive VP & Chief Scientific Officer 1.94M 138.22k 1965
Ms. Kristen C. Ambrose CPA Senior VP & Chief Accounting Officer -- -- 1977
Mr. Mike Tirozzi SVP and Chief Information & Data Officer -- -- --
Susie Lisa Senior Vice President of Investor Relations -- -- --
Mr. Jonathan Biller J.D. Executive VP & Chief Legal Officer -- -- 1964
Ms. Nina Devlin Senior VP & Chief Communications Officer -- -- --

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617 341 6100 https://www.vrtx.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
5,400

Description

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Corporate Governance

Vertex Pharmaceuticals Incorporated’s ISS Governance QualityScore as of October 1, 2024 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 6; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 4, 2024 at 9:00 PM UTC

Vertex Pharmaceuticals Incorporated Earnings Date

Recent Events

Related Tickers